Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

680.40INR
17 Apr 2015
Change (% chg)

Rs1.55 (+0.23%)
Prev Close
Rs678.85
Open
Rs679.00
Day's High
Rs689.00
Day's Low
Rs672.10
Volume
2,231,820
Avg. Vol
1,728,247
52-wk High
Rs752.85
52-wk Low
Rs367.50

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited (Cipla) is an India-based global pharmaceutical company. The Company’s portfolio includes approximately 2000 products in 65 therapeutic categories with one quality standard globally. Cipla’s turnover in 2012/13 was approximately 1.5 billion USD. The Company’s research and development focus on developing products... (more)

Overall

Beta: 0.47
Market Cap(Mil.): Rs545,089.69
Shares Outstanding(Mil.): 802.96
Dividend: 2.00
Yield (%): 0.29

Financials

  CIPL.NS Industry Sector
P/E (TTM): 46.21 40.93 41.57
EPS (TTM): 14.69 -- --
ROI: -- 16.70 16.05
ROE: -- 17.23 16.88
Search Stocks

BUZZ-Investors take tactical refuge in Indian pharma ahead of Fed

** Pharmaceutical stocks, traditionally seen as defensives, gain on churning ahead of the U.S. Federal Reserve policy meeting outcome on Wednesday

17 Mar 2015

Germany's Boehringer loses India patent on lung drug to Cipla

MUMBAI - India has revoked a patent on German pharmaceutical company Boehringer Ingelheim's lung drug Spiriva and ruled in favour of domestic drugmaker Cipla Ltd, in the latest setback for a multinational drugmaker operating in India.

10 Mar 2015

Germany's Boehringer loses India patent on lung drug to Cipla

MUMBAI, March 10 - India has revoked a patent on German pharmaceutical company Boehringer Ingelheim's lung drug Spiriva and ruled in favour of domestic drugmaker Cipla Ltd , in the latest setback for a multinational drugmaker operating in India.

10 Mar 2015

BUZZ-India's pharma shares gain on foreign buying, mgmt commentary

** Lupin gains 3.5 pct, Glenmark Pharmaceuticals is up 2.3 pct, while Cipla surges 5 pct

13 Feb 2015

BRIEF-India's Cipla agrees to buy 60 pct stake in Jay Precision for $15 mln

* Says agrees to buy 60 percent stake in Jay Precision Pharmaceuticals Pvt Ltd for 960 million rupees ($15.44 million) in cash

12 Feb 2015

Cipla Q3 net profit up 15.5 pct

MUMBAI - Cipla Ltd, India's fourth-largest drugmaker by sales, on Thursday reported a 15.5 percent rise in its third-quarter profit, slightly lagging analysts' estimates.

12 Feb 2015

India's Cipla Q3 net profit up 15.5 pct

MUMBAI, Feb 12 - Cipla Ltd, India's fourth-largest drugmaker by sales, on Thursday reported a 15.5 percent rise in its third-quarter profit, slightly lagging analysts' estimates.

12 Feb 2015

BUZZ-India's Cipla surges to record high on generic Nexium supply hopes

** India's Cipla rises as much as 4.8 pct to record high of 710 rupees

27 Jan 2015

Delhi High Court bars Cipla from selling copy of Novartis respiratory drug

MUMBAI - The Delhi High Court has barred generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.

13 Jan 2015

India court bars Cipla from selling copy of Novartis respiratory drug

MUMBAI - An Indian court has barred Indian generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.

13 Jan 2015

Earnings vs. Estimates

Search Stocks